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Abstract
There is convincing evidence that environmental stress plays a significant role in modifying both mental and physical health. The biological mech-
anisms linking stress to ill health are not fully understood, but significant evidence points to a central role of the stress axes; the hypothalamic–
pituitary–adrenal (HPA) axis and the sympathetic nervous system. Together these two systems link the brain and the body and are crucial in main-
taining homeostasis as well as improving an organism’s survival chances in the face of environmental challenge. There is evidence of altered HPA axis
function in people with a range of mental disorders, and this may in part explain the poor physical health of people with psychotic, mood and anxiety
disorders. This paper systematically reviews HPA axis function in people with schizophrenia and relates this to the pattern of physical health seen in
this disease. In summary, the evidence suggests people with schizophrenia can experience both hyper- and hypo-function of the HPA axis. It is likely
that this contributes to the pattern of poor physical health and premature mortality suffered by people with schizophrenia, in particular the high rates
of cardiovascular and metabolic disturbance.
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Introduction
Stress has a powerful eﬀect on both the brain and the body
(McEwen, 1998) and has a signiﬁcant role in the development
and course of mental and physical illness (Burcusa and
Iacono, 2007; Cohen et al., 2007; Kendler et al., 1999;
McEwen and Stellar, 1993; Walker and Diforio, 1997).
Evidence has accumulated that chronic stress has signiﬁcant
eﬀects on both brain structure and function (McEwen and
Gianaros, 2010; Pruessner et al., 2010; Sapolsky, 2003) and
on whole body systems (Rosmond, 2005), cumulating in dis-
ease and increased mortality. Stress, which can be both phys-
ical and psychological, has been deﬁned as a state where
homeostasis is threatened or perceived to be threatened, and
animals have developed a range of behavioural and physio-
logical responses in order to maintain homeostasis in situa-
tions of stress (Chrousos and Gold, 1992). The brain is the
central organ in the adaptation to stress, since it determines
what is threatening or benign. The biological response to
stress is then mediated through the hypothalamic–pituitary–
adrenal (HPA) axis and the sympathetic nervous system
(SNS), which invoke a number of adaptive behavioural and
physiological changes that enhance survival of the individual
in the face of stress. Together the stress axes inﬂuence many
bodily processes, including cardiovascular function and the
provision of energy substrates, and that they are tightly
regulated suggests that any over or under activity may be
detrimental to health (Chrousos and Gold, 1992). For
detailed reviews of the function of the stress axes and the
central role of the brain the reader is referred to Tsigos and
Chrousos (2002) and McEwen and Gianaros (2010).
Over recent decades science has begun to unravel the bio-
logical mechanisms by which stress can harm the brain and
body, aiding our understanding of the aetiology of both
mental and physical ill health. Since the adaptive response
to stress is designed to increase survival, it follows that a
dysfunctional stress response (over or underactivity) may be
damaging to an individual. One way of considering this is the
concept of allostatic load. The adaptive response has also
been termed allostasis (Sterling and Eyer, 1988), while allo-
static load represents the wear and tear the body experiences
when repeated allostatic responses are activated (or not)
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Allostatic load can occur in a number of ways, such as expo-
sure to frequent or chronic stressors, invoking a frequent or
chronic stress cascade. For example, frequent increases in
blood pressure may accelerate atherosclerosis or trigger myo-
cardial infarction in susceptible individuals. (McEwen, 1998).
Failure to deactivate the stress response within a dysfunctional
stress system could lead to over exposure to the eﬀects of glu-
cocorticoids and/or catecholamines. This can result in the
development of central obesity, type 2 diabetes, hypertension
and cardiovascular disease (Rosmond, 2005). The result of
overexposure to cortisol is demonstrated in Cushing’s syn-
drome,adisordercharacterizedbychronichypercortisolaemia
and the features of the metabolic syndrome (Shibli-Rahhal
et al., 2006). The absence of an appropriate stress response
or hypofunction of the HPA axis can also be damaging
(Heim et al., 2000; Raison and Miller, 2003). For example, a
lack of the usual anti-inﬂammatory cortisol response to stress
mayallowprolongedexposuretoSNS-stimulatedimmuneand
inﬂammatory function, causing disease. Stress may also have
indirecteﬀectsonphysicalhealth,asexposuretopsychological
stress may modify an individual’s health behaviours and
increase risk for the development of disease. For example,
people confronted with chronic stress in daily life may
engage in unhealthy behaviours such as smoking, alcohol
and substance misuse and poor dietary choices; they may
also be less likely to engage in physical activity (Hemingway
and Marmot, 1999; Oliver et al., 2000; Steptoe et al., 1996).
There is good evidence that the HPA and SNS axes are
dysfunctional in a range of mental disorders (Brown et al.,
2009; Fujibayashi et al., 2009; Meewisse et al., 2007; Walker
et al., 2008; Watson and Mackin, 2006), and this dysfunction
therefore provides a possible mechanism for the common
co-existence of poor mental and physical health (Golden,
2007; Goldston and Baillie, 2008; Mondelli and Pariante,
2008; Ryan and Thakore, 2002). The evidence for HPA dys-
function in schizophrenia has been reviewed in the context of
the diathesis–stress model of schizophrenia (Walker and
Diforio, 1997; Walker et al., 2008), but to date this evidence
has not been systematically reviewed.
Thus, the aim of this paper is twofold:
To systematically review the evidence for HPA axis dysfunc-
tion in patients with schizophrenia
To assess whether any evidenced dysfunction is contributing
to the poor physical health of people with schizophrenia.
Methods
Determining HPA axis function in humans is challenging.
Markers of basal as well as stimulated HPA activity are
required in order to fully reveal and understand the mecha-
nisms (Kudielka and Wust, 2010). Therefore controlled studies
thatmeasuredoneormoreofthefollowingvariablesorutilized
theHPA axisprobes listed below weresystematicallyreviewed:
Levels of basal cortisol, adrenocorticotropin hormone
(ACTH) or corticotropin-releasing hormone (CRH) as a
single measure or over time
CRH test
Dexamethasone (DEX)/CRH test
Eﬀects of psychological stressors on HPA function
Dexamethasone suppression test (DST).
The search was restricted to peer-reviewed journals and
sought published articles that measured the above variables
in adult (aged>18 years), schizophrenia patients. The OVID
databases of Medline, Embase and Psychinfo were searched
from the earliest time point to March 2010 by a qualiﬁed
information scientist. Search terms included hypothalamo–
hypophyseal system, hydrocortisone, adrenocorticotropin
hormone, corticotropin-releasing hormone, all combined
with schizophrenia. Abstracts were reviewed by one author
(AB) and the full, original article obtained for any study that
examined the areas of interest. Studies were examined for any
potential cohort overlap with previous publications by the
same group. Where cohorts overlapped, only the larger
study was included. Authors were contacted if overlap was
unclear. The reference list of all relevant articles and review
articles was also searched for any additional studies not iden-
tiﬁed during the OVID searches. Following these searches,
studies were included in the systematic review only if they
met the following inclusion criteria:
Data published from 1980 onwards on the basis that studies
reported before this date did not use control groups for
basal measures and most also utilized outdated assay
methods to detect levels of HPA secretories which may
now be considered inaccurate
Written in English
Patients diagnosed with schizophrenia using structured diag-
nostic interviews such as DSM or RDC criteria
Schizophrenia diagnosed in at least 90% of the reported psy-
chiatric cohort. If other diagnostic categories were
included in the cohort (e.g. major depression or schizo-
phreniform disorder) and accounted for more than 10%
of the total sample, results from the schizophrenia cohort
reported separately
The assay used to measure physiological outcomes was
reported
For studies of basal HPA functioning, blood, cerebrospinal
ﬂuid (CSF), salivary or urinary measures taken as a single
sample or at multiple time points and compared with non-
psychiatric controls. The diﬀerence between schizophrenia
patients and controls was reported
Minimum of 10 schizophrenia patients in studies using the
DST. The 1.0mg DST was used with a post-DEX cortisol
cut-oﬀ for non-suppression of 138nmol/L (5ug/dL).
Studies using only one time point for measurement of
post-DEX cortisol before 16:00 were excluded. The rate
of non-suppression must have been reported. Studies uti-
lizing the DST did not require a control group since the
rate of non-suppression of cortisol during this test in the
general population is well documented
Studies measuring the response of the HPA axis to psycho-
logical stress used a psychological stressor with the ability
to produce a measurable stress response as assessed by the
cortisol, ACTH or CRH response in a non-psychiatric
control group.
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the abstract, 786 articles were discarded either because they
were published pre-1980, did not describe the subject matter
of interest, were not written in English or were review articles
with no original data. The full published article was obtained
for the remaining 216 articles. Of these, 160 met the inclusion
criteria and were included in the systematic review. Fifty-six
articles were rejected as follows:
Schizophrenia patients less than 90% of the psychiatric
cohort or data for schizophrenia patients were not
reported separately (n¼16)
Fewer than 10 patients in DST studies (n¼13)
Inadequate control group (n¼8)
Results for schizophrenia patients not speciﬁcally reported
(n¼6)
Overlap with a previously reported cohort (n¼5)
Studies did not use the deﬁned DST method (n¼5)
Inadequate description of study methods (n¼3).
Data were extracted from the included studies and tabu-
lated to aid interpretation. All extracted data were veriﬁed
during a data integrity review undertaken by a third person
(see Acknowledgements). Basic analysis was performed and
conclusions on HPA functioning in schizophrenia patients
were drawn. Any evidenced dysfunction was evaluated with
respect to its possible eﬀects on physical disease and mortality
by performing a brief and selected review of the evidence for
the role of HPA axis dysfunction in the aetiology of physical
disease.
Results
Basal cortisol
In total, 77 studies measuring basal cortisol in 1928 schizo-
phrenia patients and 1699 controls met the stated inclusion
criteria (Tables 1, 2 and 3; ﬁve studies appear in more than
one table, either because they reported on more than one
cohort of schizophrenia patients or because 24-h cortisol
levels were similar for schizophrenia patients and controls
but signiﬁcant diﬀerences were found at a single time
point). These studies were heterogeneous in their methodol-
ogy and outcomes, making interpretation of the results com-
plex. Variations in methods included the time of cortisol
measurement and whether patients were medicated or drug
free, symptomatic or stable.
Analysis of all 77 studies combined provided evidence that
mean basal cortisol levels are elevated in some but not all
schizophrenia patients. Mean basal cortisol was statistically
signiﬁcantly elevated in schizophrenia patients compared with
controls (area under the curve (AUC) or at a single time
point) in 34/77 (44.2%) studies. Basal cortisol was not signif-
icantly diﬀerent between schizophrenia patients and controls
in 44/77 (57.1%) studies, and basal cortisol was signiﬁcantly
lower in schizophrenia patients than in controls in 4/77
(5.2%) studies. Elevated basal cortisol was reported in studies
including acutely psychotic patients, for example Albus et al.
(1982), Gil-Ad et al. (1986), Muck-Seler et al. (2004) and
Whalley et al. (1989), in patients described as more stable
as reported by Breier and Buchanan (1992), Gallagher et al.
(2007), Yilmaz et al. (2007), and in patients with prominent
negative symptoms and an absence of positive symptoms as
demonstrated in Altamura et al. (1989) and Shirayama et al.
(2002). These studies demonstrate that elevated cortisol can
be present in schizophrenia patients at diﬀerent phases of the
illness and with diﬀerent levels and types of symptoms.
Studies measuring 24-h cortisol or cortisol measured
over multiple time points
As cortisol is secreted in a circadian rhythm over a 24-h
period, studies that measured 24-h cortisol level or measured
cortisol over several time points spanning at least 3h within a
24-h period were examined separately. This analysis would
indicate if diﬀerences in cortisol are sustained over time
rather than at a single time point, and might also detect dif-
ferences in cortisol secretion at diﬀerent times of the day,
indicating disruption to the normal circadian rhythm.
In total, 18 studies including 421 schizophrenia patients
measured basal cortisol over at least a 3-h time interval.
Four of these studies found evidence of increased cortisol in
schizophrenia patients that was not sustained, i.e. a diﬀerence
in cortisol level was found at only one time point measured.
Christie et al. (1986) and Whalley et al. (1985) found elevated
afternoon but not morning or evening cortisol in schizophre-
nia patients recently admitted to hospital (p<0.05 and
p<0.02, respectively). The study reported by van Cauter
et al. (1991) found no diﬀerence in 24-h cortisol in drug-
free, recently hospitalized, acutely ill patients but the early
sleep mean (00:00–04:00) was signiﬁcantly higher in schizo-
phrenia patients than in controls. Likewise the study by Jiang
and Wang (1998) found no diﬀerence in mean 24-h cortisol in
medicated, acutely ill inpatients, but found a signiﬁcantly
higher cortisol level in schizophrenia patients between
02:00 and 03:00. Seven of the 18 (38.9%) studies found evi-
dence for sustained elevation or elevation of cortisol at more
than one time point in schizophrenia patients. Morphy et al.
(1985) found elevated cortisol in acutely ill schizophrenia
patients relative to controls at both 08:00 (p<0.01) and
16:00 (p<0.001), as did Altamura et al. (1989), 08:00
(p<0.05) and 16:00 (p<0.001), in patients with prominent
positive or negative symptoms. Whalley et al. (1989) reported
signiﬁcantly elevated cortisol at morning, afternoon and eve-
ning measures in drug-free, acutely psychotic patients
(p<0.05). Gil-Ad et al. (1986) found evidence of elevated
cortisol when measured at 3-h intervals from 07:00–22:00
in acutely psychotic schizophrenia patients. Levels were
signiﬁcantly elevated compared with controls at 07:00,
10:00, 19:00 and 22:00 (p<0.05) and at 13:00 (p<0.01).
Monteleone et al. (1992) reported a 16-h cortisol proﬁle
(AUC) that was signiﬁcantly higher in moderately ill, chronic
schizophrenia patients than in controls (p<0.001). Two stud-
ies measured cortisol between 13:00 and 16:00, a measure
that strongly correlates with 24-h cortisol (Halbreich et al.,
1982). Ryan et al. (2004b) reported signiﬁcantly higher AUC
cortisol in mildly ill, ﬁrst-episode, drug-naive schizophrenia
patients (p<0.01), and Gallagher et al. (2007) reported after-
noon cortisol to be signiﬁcantly higher in symptomatically
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Study
SCH
(n)
Medication, illness phase, symptoms if
stated Cortisol measure and time if stated p-value and comments
Albus et al. (1982) 12 Drug free 4 weeks, acutely psychotic Plasma cortisol time not stated p<0.05
Ferrier et al. (1982) 15 Drug free >1 year, chronic SCH, inpatients Plasma cortisol 00.00 p<0.01
Morphy et al. (1985) 18 FGA, newly admitted Plasma cortisol 08.00 and 16.00 p<0.01 & p<0.001
Whalley et al. (1985) 13 Drug free 6 months, newly admitted Plasma cortisol am, pm and evening p<0.02pm only
Christie et al. (1986) 24 Drug free 3 months, acutely psychotic,
admitted
Plasma cortisol am, pm and evening p<0.05pm only
Gil-Ad et al. (1986) 10 Drug free 10 days, acutely psychotic Plasma cortisol 07.00–22.00
(3 hourly)
p<0.05 except 16.00
Altamura et al. (1989) 54 FGA, inpatients Plasma cortisol 08.00 and 16.00 p<0.05 & p<0.001  ve
SCH>þ SCH 16.00
p<0.01
Whalley et al. (1989) 26 Drug free 3 months, acutely psychotic,
admitted
Plasma cortisol am, pm and evening p<0.05 am, pm and
evening
van Cauter et al. (1991) 9 Neuroleptic free 9 weeks, hospitalized,
BPRS 43–79
24 hour plasma cortisol every 15min p<0.004 (00.00–04.00)
24 hour mean cortisol
SCH¼CON
Breier and Buchanan
(1992)
9 Drug free 8–77 days, stable, chronic
outpatients
Plasma cortisol 09.00 on 2 days p¼0.04 (day 1) SCH¼CON
(day 2)
Monteleone et al. (1992) 7 Drug free  3 weeks, outpatients, admitted
for study. BPRS 41.1
Plasma cortisol 20.00–12.00
(16 hours)
p<0.0002 (16 hour corti-
sol profile)
p<0.001 (cortisol AUC)
Lammers et al. (1995) 24 9 patients drug free, 7 FGA, 8 SGA.
Mean BPRS 41
Plasma cortisol between 14.00–15.00 p<0.01
Abel et al. (1996) 13 First-episode drug-naı ¨ve inpatients
BPRS 39.2
Plasma cortisol between 08.00–09.00 p¼0.0059
Jiang and Wang (1998) 21 All patients receiving FGA. Inpatients.
BPRS 48.3
24 hour plasma cortisol p<0.01 (02.00 and 03.00)
AUC cortisol
SCH¼CON
Markianos et al. (1999) 31 FGA hospitalized poor treatment response
BPRS 45.0
Plasma cortisol 09.00 p¼0.001
Monteleone et al. (1999) 16 Drug free, inpatients. 9/16 patients
treatment resistant
Plasma cortisol 09.00–09.30 p<0.03
Muck-Seler et al. (1999) 86 Drug free for 7 days. Admitted Plasma cortisol 08.00 p<0.001
Meltzer et al. (2001) 51 Drug free 7 days, hospitalized 58.8%
treatment resistant. BPRS 28.7
Plasma cortisol 08.30–09.00 SCH>CON (p¼0.003)
Shirayama et al. (2002) 28 Neuroleptics. In and out patients with an
absence of positive sx. Patients split
into low (n¼14)and moderate negative
sx groups (n¼14)
Plasma cortisol between 08.30–11.30 p<0.01 (SCH moderate
negative sx) SCH low
negative sx¼CON
Thakore et al. (2002) 15 Drug naive and drug free, mostly inpatients
BPRS 22.6
Plasma cortisol 16.00 p<0.008
Ryan et al. (2003) 26 First-episode drug-naive inpatients.
BPRS 54.8
Plasma cortisol 08.00 p<0.0001
Muck-Seler et al. (2004) 20 12 drug free for 8 weeks, 8 for 7 days.
BPRS 58.5 CGI 5.2
Plasma cortisol 08.00 p<0.05
Ryan et al. (2004a) 19 Hospitalized first episode drug naive.
BPRS 32.1
Plasma cortisol 08.30 p<0.003
Ryan et al. (2004b) 12 Hospitalized first episode drug naive.
BPRS 36.7
Plasma cortisol 13.00–16.00 p<0.01 (AUC 13.00–
16.00)
Walsh et al. (2005) 10 Hospitalized first episode drug naive.
BPRS 42.9
Plasma cortisol 13.00 p<0.02
Zhang et al. (2005) 78 Drug free for 2 weeks. Treatment-resistant
inpatients. Pre-treatment PANSS  80,
post-treatment PANSS  63
Serum cortisol 07.00–09.00 p<0.01 (pre and post
treatment)
(continued)
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Study
SCH
(n)
Medication, illness phase, symptoms if
stated Cortisol measure and time if stated Comments
Brophy et al. (1983) 13 Drug free for 2 months, acutely psychotic Plasma cortisol at varying times –
Stokes et al. (1984) 13 Drug free  9 days. Recently hospitalized
chronic SCH
Plasma cortisol 08.30 and 22.00 –
Banki et al. (1985) 20 Drug free for 2 weeks. Recently hospitalized Plasma cortisol 09.00–10.00 –
Gattaz et al. (1985) 15 Neuroleptic treated, admitted CSF cortisol 09.00–10.00 –
Roy et al. (1986) 9 Acutely psychotic newly admitted chronic
SCH, tested while drug free for 2 weeks
and on fluphenazine
Plasma cortisol 20.00 No significant differences in
drug-free or medicated
patients
Whalley et al. (1986) 12 Long term neuroleptics, chronic but newly
admitted
Single plasma cortisol 11.30–12.30 –
Wolkowitz et al. (1986) 8 Drug free for 4 weeks and medicated cohorts.
Inpatients
Plasma cortisol 09.15 and 09.30 No significant differences with
drug-free, medicated or
controls
Zhou et al. (1987) 48 Drug free for 1 week. Inpatients Plasma cortisol 23.00 –
Breier et al. (1988a) 10 Drug free for 3 weeks. Chronic course,
admitted
Plasma cortisol 08.00–09.00 –
Breier et al. (1988b) 8 All receiving fluphenazine. Plasma cortisol 09.00–10.00 –
Lerer et al. (1988) 10 Drug free for 4 weeks Chronically hospital-
ized with prominent negative symptoms
but attenuated positive symptoms.
Treatment resistant. BPRS 34.2
Plasma cortisol between 08.30 and
08.45 measured prior to fen-
fluramine or placebo challenge
Trend towards higher cortisol in
SCH group on both placebo
(p¼0.1) and fenfluramine
challenge days (p¼0.06)
Davila et al. (1989) 11 FGA. Chronic and subchronic. Setting not
stated.
Plasma cortisol 08.30 and 12.30 –
Fanget et al. (1989) 23 All receiving FGA. BPRS 60.3 Plasma cortisol 24.00 (midnight) –
Wolkowitz et al. (1989) 16 Drug free for 3 weeks. Illness phase and
setting not stated
Plasma cortisol 16.00 –
Nerozzi et al. (1990) 18 Drug free 3 months. 13 acute inpatients, five
chronic outpatients
Plasma cortisol 08.00 –
(continued)
Table 1. Continued
Study
SCH
(n)
Medication, illness phase, symptoms if
stated Cortisol measure and time if stated p-value and comments
Gallagher et al. (2007) 20 Antipsychotics, stable but symptomatic.
BPRS 29.7
Plasma cortisol 13.00–16.00 p¼0.003 (13.00–16.00)
Popovic et al. (2007) 18 FGA, inpatients. PANSS 90.5 Plasma cortisol 08.00 p<0.05
SCH¼CON post
SGA treatment
Ritsner et al. (2007) 43 Inpatients, FGA and SGA. PANSS 101.7 Plasma cortisol 08.00–09.00 assessed
at baseline and after 2 and 4
weeks
p<0.001 at all time points
Spelman et al. (2007) 38 First episode drug naive, hospitalized,
BPRS 44.4
Plasma cortisol 08.30 p<0.001
Venkatasubramanian
et al. (2007)
44 All patients antipsychotic naive. Mean
SAPS 30.7 and SANS 63.1
Plasma cortisol between 08.00–09.00 p<0.001
Yilmaz et al. (2007) 66 All patients taking FGA. BPRS 17.89 Plasma cortisol between 08.30–11.30 p<0.05
Kale et al. (2010) 31 Outpatient first episode drug naive. PANSS
 105
Plasma cortisol time not stated p<0.05
Venkatasubramanian
et al. (2010)
33 Drug naive. SAPS 36.2, SANS 65.6 Plasma cortisol between 08.00–09.00 p¼0.0002
AUC, area under the curve; BPRS, brief psychiatric rating scale; CGI, clinical global impression; CON, controls; FGA, first generation antipsychotic; PANSS, positive and
negative syndrome scale; SAPS, scale for the assessment of positive symptoms; SANS, scale for the assessment of negative symptoms; SCH, schizophrenia; SGA, second-
generation antipsychotic; sx, symptoms.
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SCH
(n)
Medication, illness phase, symptoms if
stated Cortisol measure and time if stated Comments
Iqbal et al. (1991) 7 Drug free for 2 weeks. Chronic SCH inpatients
(n¼5) and outpatients (n¼2)
Plasma cortisol 10.00 –
van Cauter (1991) 9 Neuroleptic free 9 weeks, hospitalized. BPRS
43–79
24-h plasma cortisol every 15min p<0.004 (00.00–04.00)
24-h mean cortisol SCH¼CON
Kathol et al. (1992) 5 Drug free for 2 weeks. Inpatients Plasma cortisol 16.00 –
Risch et al. (1992) 32 Drug free 1 week. Illness phase not stated
but admitted for study
24-h urinary free cortisol Cortisol levels SCH 60.1 (SD 58.7)
CON 40.5 (SD 27.0)
Breier et al. (1993) 18 11/18 drug free (8–279 days). Stable out-
patients with chronic course of illness.
BPRS 28
Single plasma cortisol 08.00–09.00 –
Krystal et al. (1993) 12 Drug free for 2 weeks. Hospitalized, acute
exacerbation, chronic SCH
Plasma cortisol time not stated –
Rao et al. (1995) 116 SCH inpatients majority acutely psychotic.
21 were drug naive, 68 drug free for  3
days, 25 FGA. Study began after at least 3
days in hospital
Plasma cortisol
13.00, 16.00, 19.00, 23.00,
03.00, 07.00, 10.00, 13.00
Daily mean derived from cosinor
analysis mmol/L
Wik (1995) 16 Drug free for 3 weeks. Newly admitted, then
treated with FGA
Plasma cortisol 08.00 before and
after FGA treatment
Before treatment SCH¼CON
After treatment SCH<CON
(p<0.001)
Wilke et al. (1996) 20 Antipsychotic treated. Mean PANSS 59.0 Serum cortisol –
Kudoh et al. (1997) 22 All receiving FGA, chronic but stable Plasma cortisol timed in relation to
anaesthesia for elective surgery
–
Maguire et al. (1997) 7 Stable residual schizophrenia on depot
antipsychotics
Single plasma cortisol 09.00–10.00 –
Elman et al. (1998) 13 FGA. Stable chronic outpatients admitted for
study
Plasma cortisol (morning) –
Jansen et al. (1998) 10 All patients receiving antipsychotics mostly
SGA. 5 inpatients, 5 outpatients
Salivary cortisol between
10.00–16.00
–
Jiang and Wang (1998) 21 Inpatients, all receiving FGA. BPRS 48.3 24-h plasma cortisol p<0.01 (02.00 and 03.00)
AUC cortisol SCH¼CON
Kudoh et al. (1999) 25 All patients receiving antipsychotics.
Chronic SCH
Plasma cortisol 08.30 –
Duval et al. (2000) 41 Drug free for 2 weeks. Inpatients. BPRS 59.4 Plasma cortisol 08.00 –
Jansen et al. (2000) 18 17 receiving SGA and 1 FGA. Outpatients,
PANSS 68.39
Salivary cortisol 08.00–20.00 every
2 hours
No significant differences at
08.00 or across whole day
Hundt et al. (2001) 7 Drug free for 7 days. Inpatients with nega-
tive and without psychotic symptoms.
BPRS 14.6, SANS 14.4
Plasma cortisol 09.00–11.00
(every 30min)
–
Lee et al. (2001) 5 Drug free for 7 days. Admitted with chronic
SCH. BPRS 41
Plasma cortisol 21.00 –
Kaneda et al. (2002) 53 Chronically medicated inpatients. Anxiety
similar to controls
Plasma cortisol 06.00–07.00
Kudoh et al. (2002) 50 FGA treated, stable chronic SCH Plasma cortisol timed in relation to
anaesthesia for orthopaedic
surgery
–
Shirayama et al. (2002) 28 Neuroleptics. In and outpatients with an
absence of positive sx. Patients split into
low (n¼14) and moderate negative sx
groups (n¼14)
Plasma cortisol between 08.30–
11.30
p<0.01 (SCH moderate
negative sx)
SCH low negative sx¼CON
Yazici et al. (2002) 58 Drug free for 1 week. Recently
admitted. Mean BPRS  25,
SAPS  30, SANS  60
Plasma cortisol 09.00 –
Duval et al. (2003) 20 9 drug naive, 11 drug free for 2 years.
Acutely psychotic inpatients
Plasma cortisol 09.00 on 2 days Not significantly different on
either day tested
(continued)
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studies by Davila et al. (1989), Jansen et al. (1998, 2000),
Hundt et al. (2001) Rao et al. (1995), Risch et al. (1992),
and Stokes et al. (1984), all found no evidence of diﬀerences
in cortisol between patients and controls at any of the time
points measured.
Risch et al. (1992) reported no statistically signiﬁcant dif-
ference in 24-h, urinary free cortisol between patients and
controls but this was probably due to the large variance in
cortisol levels: the mean 24-h urinary free cortisol values in
the schizophrenia (n¼32) and control groups (n¼73) were
60.1 (standard deviation (SD) 58.7) and 40.5 (SD 27.0) mg/dL,
respectively. In the largest study reported (Rao et al. 1995),
116 drug-free (for at least 3 days), drug-naive and antipsycho-
tic-treated patients were hospitalized for crisis intervention or
psychosis before blood cortisol was measured over 24h. No
signiﬁcant diﬀerences in cortisol secretion over the 24-h
period were found versus controls, suggesting cortisol secre-
tion was normal in this group. In studies by Jansen et al.
(1998, 2000), most schizophrenia patients were taking
second-generation antipsychotics, which were likely to have
had an eﬀect on cortisol level.
Basal cortisol in drug-naive patients
Antipsychotic medications may inﬂuence cortisol levels.
Evidence in healthy subjects suggests this eﬀect is minimal
with ﬁrst-generation drugs but signiﬁcant with second-genera-
tion antipsychotics (Cohrs et al., 2006). To examine basal
cortisol in patients without the inﬂuence of antipsychotic
medication, ﬁrst-episode, drug-naive schizophrenia patients
were analysed as a group. Eleven studies measured basal cor-
tisol in such patients (Abel et al., 1996; Kale et al., 2010; Ryan
et al., 2003, 2004a, 2004b; Spelman et al., 2007; Strous et al.,
2004; Taherianfard and Shariaty, 2004; Venkatasubramanian
et al., 2007, 2010; Walsh et al., 2005). In one of these studies
(Taherianfard and Shariaty, 2004), basal cortisol was signiﬁ-
cantly lower in schizophrenia patients than in controls. Basal
cortisol levels were similar in schizophrenia patients and con-
trols in the study by Strous et al. (2004). In the other nine
studies, basal cortisol was signiﬁcantly elevated compared
with controls. Collectively, these nine studies included 226
of the 312 (72.4%) ﬁrst-episode drug-naive patients studied,
indicating that elevated cortisol secretion is a common ﬁnding
in these patients.
Table 2. Continued
Study
SCH
(n)
Medication, illness phase, symptoms if
stated Cortisol measure and time if stated Comments
Goyal et al. (2004) 10 Most patients taking antipsychotics, 5
prominent positive, low negative sx, 5
prominent negative, low positive sx
Plasma cortisol 08.00 No significant difference between
positive and negative
Ritsner et al. (2004) 40 15 received SGA, 15 FGA and 10 both SGA
and FGA. Admitted patients but stable.
Mean PANSS 68.4
Plasma cortisol 08.00–09.00 –
Strous et al. (2004) 37 Drug free, first episode acutely psychotic
inpatients. PANSS 75.2
Plasma cortisol 08.00–10.00
Brunelin et al. (2008) 15 Remitted outpatients receiving SGA.
Admitted for study
Plasma cortisol 09.00 –
Brenner et al. (2009) 30 All patients taking antipsychotics. Stable
outpatients
Salivary cortisol 14.00 –
CSF¼cerebrospinal fluid, SD¼standard deviation. For other abbreviations, see Table 1.
Table 3. Studies finding basal cortisol significantly lower in schizophrenia patients than controls
Study SCH
Medication, illness phase, symptoms
if stated Cortisol measure and time if stated p value and comments
Gattaz et al. (1985) 13 Drug free 3–4 weeks. Admitted CSF cortisol 09.00–10.00 p<0.05
Monteleone et al.
(1994)
18 1/18 drug free, rest treated with FGA.
Chronic SCH inpatients.
SAPS 40, SANS  37
Plasma cortisol 08.00 measured in
November, February and May
SCH<CON at all 3 measurements
(p<0.001)
Wik (1995) 16 Drug free for 3 weeks. Newly admit-
ted, then treated with FGA
Plasma cortisol 08.00 before and
after FGA treatment
Before treatment SCH¼CON
After treatment SCH<CON
(p<0.001)
Taherianfard and
Shariaty (2004)
49 Drug free on first admission. Illness
severity not stated
Plasma cortisol 08.00 pre treatment,
after 3 weeks’ treatment with FGA
and at recovery
SCH<CON at all 3 phases of illness
(p¼0.0073)
For abbreviations, see Table 1.
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Only one published study, including nine schizophrenia
patients and 27 controls, utilized the CRH test (Roy et al.,
1986) (Table 4). Six of the patients had been taking ﬂuphen-
azine for at least 6 months on entry into the study and were
studied whilst on medication and then at least 2 weeks after
discontinuation of medication. Three patients were studied
medication free at study entry, and two of these were also
evaluated after at least 2 weeks of ﬂuphenazine treatment.
Whilst patients were drug free, ACTH and cortisol response
to CRH infusion was similar to that in controls. Treatment
with ﬂuphenazine had no eﬀect on response to CRH.
Dexamethasone/CRH test
Just two studies employing the DEX/CRH test in schizophre-
nia were identiﬁed. One of these (Heuser et al., 1994) was
excluded as data for the 24 schizophrenia patients were com-
bined with those from patients with other diagnoses. Details
of the only other study identiﬁed (Lammers et al., 1995) of 24
schizophrenia patients and 24 controls are provided in
Table 4. Basal cortisol was statistically signiﬁcantly greater
in patients than in controls (p<0.01) and basal ACTH
trended towards being higher in patients (p<0.08). Peak cor-
tisol following DEX and CRH (p<0.02) and cortisol AUC
14:00–18:00 following DEX and CRH was signiﬁcantly
greater in schizophrenia patients than controls (p<0.04).
There was no evidence for a diﬀerence in ACTH AUC fol-
lowing CRH infusion between patients and controls.
Effects of psychological stress on the HPA
axis in schizophrenia
Six studies meeting the inclusion criteria for measuring the
eﬀects of psychological stress on HPA function were identi-
ﬁed. These included 89 patients with schizophrenia and 144
controls (Table 5). The study by Albus et al. (1982) used a
combination of psychological and physical stressors, while
Table 4. Studies using the CRH and DEX CRH test in schizophrenia subjects
Study and test Population characteristics Medication and illness phase Test details Results
Roy et al.
(1986)
CRH test
9 admitted SCH patients.
4 male, 5 female
Mean age 30.0
(range 22–53) 27 CON
All acutely psychotic,
3 patients were medica-
tion free at admission and
6 patients were medi-
cated. Of the 8 medicated
patients, only 1 was in
remission
All 9 patients were studied
medication free
( 2weeks) and 8 whilst on
neuroleptics. 1mg/kg CRH
intravenously adminis-
tered at 20.00. Blood
sampled for ACTH and
cortisol at regular inter-
vals over 180min
Basal cortisol SCH¼CON (4/9 unmedi-
cated patients had basal cortisol 2 SD
above the controls mean) Basal ACTH
SCH¼CON
CRH while drug free
In the overall SCH group, ACTH and
cortisol response to CRH was normal
2 patients with high basal cortisol had
an ACTH response well below the mean
for the group although within the
normal range
Trend towards a significant negative
correlation between psychosis rating
and ACTH response (r¼ 0.42,
p<0.1)
CRH while medicated
Treatment with fluphenazine had no
effect on basal ACTH or cortisol.
Response of ACTH and cortisol follow-
ing CRH was not significantly different
to controls
Lammers
et al. (1995)
DEX/CRH test
24 SCH patients
6 males, 8 females
mean age 34 (SD 9)
24 CON
9 patients were drug free
for 3 months; the rest
were treated with cloza-
pine (n¼8) sulpride
(n¼1) and typical neuro-
leptics (n¼6) Mean BPRS
41 (15)
Patients given 1.5mg DEX
at 23.00. Following day
at 15.00 100mg CRH was
infused. Blood was sam-
pled at regularly from
14.00 to 18.00 for mea-
surement of ACTH and
cortisol DST NS prior to
CRH measured at 14.00–
15.00 (cort>110nmol/L)
Basal cortisol SCH>CON (p<0.01)
Basal ACTH SCH tended>CON
(p<0.08)
DST NS prior to CRH 3/24 (13%) SCH, 0
CON
DST NS following CRH SCH 6, CON 5
Total DST NS SCH 9/24 (38%) CON 5/24
(21%)
AUC cortisol following CRH SCH>CON
(p<0.04)
Peak cortisol following CRH SCH>CON
(p<0.02)
ACTH following CRH SCH¼CON
For SCH, AUC cortisol post-CRH was
significantly greater in unmedicated
than medicated patients (p<0.05)
ACTH, adrenocorticotropin hormone, CRH, corticotropin releasing hormone, DEX, dexamethasone, DST NS, non suppression of cortisol following DEX. For other abbreviations,
see Tables 1 and 2.
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(immersion of a limb in iced water), which is reported to
invoke an HPA response via both psychological and physical
components (Bullinger et al., 1984). The study reported by
Breier et al. (1988a) measured response to the psychological
stress associated with lumbar puncture. The remaining studies
(Brenner et al., 2009; Jansen et al., 1998, 2000) all used a
public speaking task as the psychological stressor. The results
from ﬁve of these studies (Albus et al., 1982; Breier et al.,
1988a; Goldman et al., 2007; Jansen et al., 1998, 2000) were
consistent, indicating that people with schizophrenia have a
blunted cortisol response to psychological stress compared
with controls. In the remaining study (Brenner et al., 2009),
there was a trend towards a lower cortisol response to psy-
chological stress in schizophrenia patients. Two of the studies
(Breier et al., 1988a; Goldman et al., 2007) also measured
ACTH and both found that this too had a blunted response
to stress.
The dexamethasone suppression test in schizophrenia
The search identiﬁed 85 studies including 2722 schizophrenia
patients that met the inclusion criteria, as presented in
Table 6. Non-suppression of cortisol following DEX ranged
from 0–81%. From the total group of schizophrenia patients
studied, 731/2722 (26.9%) were classiﬁed as non-suppressors.
Since antipsychotic medication may aﬀect DST results
(Tandon et al., 1991), medicated and drug-free patients
were analysed separately. For non-medicated schizophrenia
patients (no neuroleptic medication for  2 weeks prior to
the DST), 227/773 (29.4%) were classiﬁed as non-suppres-
sors. Of the 1949 medicated schizophrenia patients, 504
(25.9%) were classiﬁed as non-suppressors, suggesting that
antipsychotic medications themselves had little eﬀect on
DST results.
Several studies correlated symptoms such as depressive,
negative and positive symptoms with DST outcomes, as
Table 5. Studies measuring HPA axis response to psychosocial stress in schizophrenia patients
Study Population characteristics
Test details and outcome HPA
measures Results
Albus et al. (1982) 12 acutely psychotic, SCH
patients, drug free for 4 weeks
27 CON
Cold pressor test, noise,
mental arithmetic, active
relaxation
Cortisol response
Schizophrenia patients had significantly higher cortisol
levels than controls at rest and during the tests
(p<0.05)
Schizophrenia patients had a diminished cortisol
response to stress compared with controls
Breier (1988a) 10 drug free (>3 weeks), chronic
SCH patients
8 CON
Stress associated with lumbar
puncture at 08.00–09.00
Plasma cortisol and ACTH
Basal cortisol SCH¼CON
SCH patients had no significant elevations in plasma
cortisol or ACTH during lumbar puncture
CON subjects had significant increase in ACTH
(p<0.05) and cortisol (p<0.05)
15-min cortisol change SCH<CON (p<0.05)
Level of psychosis in SCH patients was negatively
correlated with ACTH level, i.e. higher stress-related
ACTH levels were associated with lower level of
psychosis
Jansen et al. (1998) 10 SCH in and outpatients
receiving antipsychotics
10 CON
Public speaking task
Salivary cortisol
Basal cortisol SCH¼CON
SCH patients had a significantly smaller salivary corti-
sol response to stress than CON (p¼0.033)
Jansen et al. (2000) 18 medicated SCH outpatients
21 CON
Public speaking task and
exercise (10min bike
home trainer)
Salivary cortisol
Basal and cortisol day profile SCH¼CON
Salivary cortisol response to public speaking SCH<CON
(p<0.01)
Salivary cortisol response to exercise SCH¼CON
Goldman et al. (2007) 9 medicated SCH (2/9 schizoaf-
fective), in and outpatients
admitted at least 3 weeks
before the study and optimized
on FGA (8/9) and SGA (1/9)
medication PANSS total 57.2
12 CON
Cold pressor test performed in
the evening
ACTH (p¼0.021) and cortisol response (p¼0.001) to cold
pressor test was blunted in SCH patients relative to
controls
Brenner et al. (2009) 30 chronic but stable SCH
patients. 29 CON
Modified version of Trier
social Stress Test (TSST)
Salivary cortisol
Basal cortisol SCH¼CON
Cortisol increased significantly during the test for CON
(p¼0.002) but not for SCH (p¼0.369)
Acute cortisol response to stress SCH trend<CON
(p¼0.062). When body mass index (BMI) and psy-
chosis were controlled for cortisol response to stress,
SCH<CON (p<0.05)
AUC cortisol showed a trend for SCH to secrete less
cortisol than CON (p¼0.062)
For abbreviations, see Tables 1 and 4.
Bradley and Dinan 99Table 6. Dexamethasone Suppression Test in schizophrenia
Study
Study setting and patient
symptoms (as described)
Non-suppression
medicated patients
Non-suppression
drug-free patients
Associations with symptoms where
tested
Schlesser et al. (1980) Mostly inpatients 0/48 (0%) – –
Dewan et al. (1982) Chronic SCH 6/20 (30%) – No association of post-DEX cortisol
with HAM-D or BPRS
Rothschild et al. (1982) Psychotic inpatients 2/14 (14%) – –
Castro et al. (1983) Chronic SCH 7/23 (30%) – –
Coppen et al. (1983) Chronic SCH inpatients 10/46 (22%) – NS associated with negative not
positive symptoms
Targum (1983) Hospitalized SCH patients 1/14 (7%) –
Banki et al. (1984) Hospitalized, acutely
psychotic
13/34 (38%) – Paranoid SCH<catatonic and
hebephrenic
Berger et al. (1984) Admitted SCH patients 7/23(30%) on admission
4/21 (19%) 7–10 days
later
––
Hwang et al. (1984) SCH inpatients 2/13 (15%) – –
Meltzer et al. (1984) No details 7/36 (19%) – –
Munro et al. (1984) Residual SCH outpatients 7/46 (15%) – NS associated with depressive
symptoms
Nelson et al. (1984) Admitted SCH patients 4/14 (29%) – –
Rihmer et al. (1984) Paranoid SCH 1/20 (5%) – –
Sauer et al. (1984) Admitted SCH patients 5/20 (25%) – –
Sawyer and Jeffries
(1984)
20 SCH inpatients 7/20 (35%) – NS associated with melancholic
depression not depressed mood
Stokes et al. (1984) Hospitalized chronic SCH 2/12 (17%) –
Banki et al. (1985) Recently hospitalized SCH – 10/20 (50%) –
Baumgartner et al.
(1985)
Recently hospitalized SCH 11/22 (50%) – –
Dam et al. (1985) SCH inpatients 5/15 (33%) – –
Harris (1985) Chronic long stay SCH – 4/12 (33%) No association of negative symptoms
with NS
Herz et al. (1985) Recently admitted SCH
acutely psychotic
9/13 (69%) 1/5 (20%) of
the non-suppressors
after 7 days’ antipsy-
chotic therapy
––
Morphy et al. (1985) Admitted SCH patients 6/13 (46%)
Saffer et al. (1985) Chronic long stay SCH 10/50 (20%) – NS associated with negative
symptoms
Asnis et al. (1986) Chronic and subchronic SCH
inpatients
4/17 (24%) – –
Banki et al. (1986) Recently hospitalized SCH – 7/20 (35%) –
Cook et al. (1986) Acutely admitted SCH 5/25 (20%) – –
Doran et al. (1986) SCH inpatients – 2/13 (15%) No association of NS with depression
Hubain et al. (1986) Acute, recently admitted SCH 10/22 (45%) – –
McMahon et al. (1986) Recently admitted, acutely
psychotic chronic SCH
1/12 (8%) – –
Moller et al. (1986) Acutely psychotic SCH 12/20 (60%) day 1
7/19 (37%) day 7
6/12 (46%) day 23
– No association with depressive
symptoms. Negative correlation of
NS with severity of SCH symptoms
Pickar et al. (1986) Chronic recently admitted
SCH
– 5/24 (21%) –
Sora et al. (1986) Recently admitted SCH 7/28 (25%) – –
Tsoi et al. (1986) Chronic SCH 7/61 (11%) – NS not associated with depression,
positive or negative
Wik et al. (1986) Acutely admitted SCH 4/15 (27%) 17/21 (81%) –
Banki et al. (1987) Recently hospitalized SCH – 6/23 (26%) –
Holsboer-Trachsler et al.
(1987)
Severe, acute, admitted SCH 15/31 (48%) 1st test
4–5 days
––
(continued)
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Study
Study setting and patient
symptoms (as described)
Non-suppression
medicated patients
Non-suppression
drug-free patients
Associations with symptoms where
tested
4/31 (13%) 2nd test
4 weeks
Hwu et al. (1987) SCH inpatients 11/60 (18%) – NS associated with depression
Joseph et al. (1987) Non-depressed acute, chronic
and subchronic SCH
0/37 (0%) 2 patients
NS but compliance
with DEX unclear
––
Joyce et al. (1987) Recently admitted SCH 2/10 (20%) – –
Krishnan et al. (1987) Recently admitted SCH 2/15 (13%) – –
Pandey et al. (1987) Admitted to research unit – 4/22 (18%) –
Perenyi et al. (1987) Recently admitted SCH 6/30 (20%) – No association with anxiety/
depression
Zhou et al. (1987) Hospitalized SCH 6/48 (13%) – –
Aleem et al. (1988) SCH inpatients 6/19 (32%) – No association with depression or
negative symptoms
Coryell et al. (1988) Admitted SCH 2/13 (15%) – –
Keshavan et al. (1988) Chronic SCH 4/16 (25%) – Post-DEX cortisol positively corre-
lated with depression and dura-
tion of illness. No association
with psychosis
Kiriike et al. (1988) Outpatient and hospitalized
SCH
2/22 (9%) – –
Lu et al. (1988) SCH inpatients – 13/36 (36%) No association of pre or post-DEX
cortisol with depression
Sharma et al. (1988) SCH inpatients 8/44 (18%) No association with depression
Whiteford et al. (1988) Chronic SCH outpatients with
prominent negative
symptoms
9/40 (23%) – No association with depression or
negative symptoms
Altamura et al. (1989) SCH inpatients 22/54 (40%) – NS associated with negative
symptoms
Coryell and Zimmerman
(1989)
Recently admitted SCH 8/31 (26%) – –
Horodnicki et al. (1989) Paranoid SCH 9/20 (45%) prior to
treatment 4/20
(20%) after 4 weeks’
treatment
––
Keshavan et al. (1989) Recently admitted SCH – 3/27 (11%) No association with negative or
depressive symptoms. Trend to
association with positive symp-
toms and BPRS total score
McGauley et al. (1989) Long stay, chronic SCH
inpatients
4/28 (14%) Post-DEX cortisol associated with
negative symptoms
Tandon et al. (1989) Recently admitted SCH 0/20 (0%) after
4 weeks’ treatment
7/20 (35%) Initial NS associated with negative
symptoms NS associated with
good outcome at 4 weeks
Wolkowitz et al. (1989) SCH patients – 4/16 (25%)
Addington and Addington
(1990)
Voluntary admitted SCH 6/50 (12%) – NS associated with depression
Harris et al. (1990) Recently admitted SCH 5/35 (14%) – –
Hwu and Lin (1990) Recently admitted SCH 18/49 (37%) 1st week
admission
6/38 (16%) 3rd week
admission
4/26 (15%) 1 week
before discharge
3/32 (9%) 1-year
follow-up
––
Minas et al. (1990) Recently admitted SCH 3/20 (15%)
(continued)
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Study
Study setting and patient
symptoms (as described)
Non-suppression
medicated patients
Non-suppression
drug-free patients
Associations with symptoms where
tested
NS not associated with depression,
negative or positive symptoms
Monteleone et al. (1990) Chronic SCH inpatients 9/32 (28%) – –
Steiner et al. (1990) Newly admitted SCH 0/12 (0%) – –
Wahby et al. (1990) Recently admitted SCH – 1/10 (10%) –
Newcomer et al. (1991) SCH inpatients – 3/21 (14%) Post-DEX cortisol associated with
negative symptoms and cognitive
deficits but not depression. Post-
DEX cortisol negatively associated
with positive symptoms
Tandon et al. (1991) Recently admitted SCH 6/44 (14%) after
4 weeks’ treatment
22/58 (38%) at
baseline
Post-DEX cortisol correlated with
negative symptoms but not global
severity, positive or depressive
symptoms at baseline. No associ-
ations at 4 weeks
Coryell and Tsuang (1992) Admitted SCH 5/20 (25%) – –
Pandey et al. (1992) SCH inpatients 11/34 (32%) – –
Rybakowski and Plocka
(1992)
SCH inpatients 36/105 (34%) –
Garyfallos et al. (1993) Chronic SCH inpatients 4/30 (13%) – No significant correlations of post-
DEX cortisol with BPRS, depres-
sion or negative symptoms
Goldman et al. (1993) SCH inpatients (25%
polydipsic)
7/53 (13%) 12/53 (27%) NS was more common in polydipsic
patients during treatment with
antipsychotics (38% vs. 5%)
Jones et al. (1994) Hospitalized SCH – 12/57 (21%) Post-DEX cortisol correlated with
suicide attempt, depression, neg-
ative and positive symptoms
(BPRS þve scale 1)
Mauri et al. (1994) Acutely psychotic SCH
inpatients
6/24 (25%) – No association of NS with BPRS total
Monteleone et al. (1994) SCH inpatients 0/18 (0%)
(November DST)
– DST repeated in Feb 4/18 (22% NS)
and May 0/18 (0%)
Goldman et al. (1996) Admitted SCH – 18/49 (37%) No association of post-DEX cortisol
with family history of depression
Lewis et al. (1996) Admitted SCH – 38/96 (40%) No association with suicide attempt
Tandon et al. (1996) SCH inpatients – 14/35 (40%) Post-DEX cortisol associated with
negative symptoms but not
depressive or positive symptoms
Pivac et al. (1997) Admitted SCH 44/80 (55%) – NS similar in positive and negative
symptoms
Ismail et al. (1998) Paranoid SCH in and
outpatients
1/60 (2%) – Post-DEX cortisol correlated with
depression and BPRS but not
negative symptoms
Jiang and Wang (1998) Paranoid SCH inpatients 0/21 (0%) – –
Muck-Seler et al. (1999) Admitted SCH 43/86 (50%) – –
Duval et al. (2000) Paranoid SCH inpatients – 7/41 (17%) –
Plocka-Lewandowska
et al. (2001)
Hospitalized acute SCH 13/32 (41%)
8/32 (25%)
9 years later
– NS associated with suicide attempt
Yazici et al. (2002) Admitted SCH 24/58 (41%) – NS associated with good 1 year
outcome
Ceskova et al. (2006) First episode hospitalized SCH 3/56 (5%) after acute
treatment
9/56 (16%)
after 1 year
10/56 (18%) Trend for NS to be associated with
good outcome.
Post-DEX cortisol correlated with
negative symptoms following
acute treatment
HAM-D, Hamilton depression rating scale, NS, non suppressor of cortisol following DEX. For other abbreviations, see Tables 1 and 4.
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emerged. Of the 19 studies that looked for a correlation
between negative symptoms and non-suppression of post
DEX cortisol levels, 10 found a correlation (Altamura
et al., 1989; Ceskova et al., 2006; Coppen et al., 1983; Jones
et al., 1994; McGauley et al., 1989; Newcomer et al., 1991;
Saﬀer et al., 1985; Tandon et al., 1989, 1991, 1996), and nine
did not (Aleem et al., 1988; Garyfallos et al., 1993; Harris,
1985; Ismail et al., 1998; Keshavan et al., 1989; Minas et al.,
1990; Pivac et al., 1997; Tsoi et al., 1986; Whiteford et al.,
1988).
Seven studies found a correlation of non-suppression with
depression (Addington and Addington, 1990; Hwu et al.,
1987; Ismail et al., 1998; Jones et al., 1994; Keshavan et al.,
1988; Munro et al., 1984; Sawyer and Jeﬀries, 1984) while 15
did not (Aleem et al., 1988; Dewan et al., 1982; Doran
et al., 1986; Garyfallos et al., 1993; Keshavan et al., 1989;
Lu et al., 1988; Minas et al., 1990; Moller et al., 1986;
Newcomer et al., 1991; Perenyi et al., 1987; Sharma et al.,
1988; Tandon et al., 1991, 1996; Tsoi et al., 1986; Whiteford
et al., 1988). Goldman et al. (1996) found no association of
non-suppression with a family history of depression.
Seven studies found no correlation between positive symp-
toms and non-suppression of cortisol (Coppen et al., 1983;
Keshavan et al., 1988; Minas et al., 1990; Pivac et al., 1997;
Tandon et al., 1991, 1996; Tsoi et al., 1986), with one study
ﬁnding a positive association (Jones et al., 1994), one a trend
towards a positive correlation (Keshavan et al., 1989) and one
ﬁnding a negative association (Newcomer et al., 1991). Two
studies found an association of post-DEX cortisol with sui-
cide attempt (Jones et al., 1994; Plocka-Lewandowska et al.,
2001), while a study by Lewis et al. (1996) found no such
association.
The studies reported by Berger et al. (1984), Herz et al.
(1985), Holsboer-Trachsler et al. (1987), Horodnicki et al.
(1989), Hwu and Lin (1990), Moller et al. (1986), Tandon
et al. (1989, 1991), and Wik et al. (1986), all included a
DST performed on newly admitted psychotic patients and
then repeated following varying lengths of antipsychotic
treatment. These studies all demonstrated high non-suppres-
sion rates on admission (range 30–81%), and in each case
there was a large reduction in the percentage of non-suppres-
sors following antipsychotic treatment (range 0–46%), during
which time there was an assumed clinical improvement. In the
longest study over time, Plocka-Lewandowska et al. (2001)
found non-suppression in 41% of the acutely hospitalized
sample; 25% were non-suppressors 9 years later.
Basal measures of CRH and ACT
In total, 21 studies measured basal CRH and/or ACTH in 539
schizophrenia patients (Table 7). Basal CRH in CSF was
measured in ﬁve of these studies (Banki et al., 1987, 1992;
Nemeroﬀ et al., 1984; Nishino et al., 1998; Risch et al.,
1992). Four of these found basal CRH to be similar in schizo-
phrenia and controls, and in only one of these studies (Banki
et al. 1987) was there any evidence for increased basal CRH in
schizophrenia. However, in this study, 6/23 (26%) schizo-
phrenia patients had a CRH value higher than the greatest
value in any control subject. Thus, the mean CRH for
schizophrenia patients was statistically signiﬁcantly higher
than that for control subjects (p<0.001), but the authors
suggested that the mean value was skewed by the data from
the three schizophrenia patients with extremely high CRH
values.
Seventeen of the studies measured basal ACTH. The stud-
ies reported by Duval et al. (2000, 2003), Elman et al. (1998),
Hundt et al. (2001), Risch et al. (1992), Roy et al. (1986), van
Cauter et al. (1991) (which measured 24-h ACTH), and Yazici
et al. (2002) all found no diﬀerence between basal ACTH in
schizophrenia patients and controls. These studies also all
reported no diﬀerence in cortisol in these patients indicating
a normal eﬀect of ACTH on cortisol secretion. In addition:
Kathol et al. (1992) found a trend towards lower basal ACTH
in schizophrenia patients than controls (p¼0.07) but sim-
ilar cortisol levels in patients and controls
Kudoh et al. (1997) reported signiﬁcantly lower basal ACTH
(p<0.05) but similar cortisol in schizophrenia patients
and controls
Brambilla et al. (1984) found non-signiﬁcantly higher basal
cortisol levels in schizophrenia patients compared with
controls: 14/37 (38%) schizophrenia patients had an
ACTH level above the range of the controls
Lammers et al. (1995) reported basal ACTH tended to be
higher in schizophrenia patients (p<0.08), resulting in a
signiﬁcantly higher basal cortisol level (p<0.01)
Kaneda et al. (2002) and Brunelin et al. (2008) found signif-
icantly elevated ACTH in patients compared with con-
trols (p<0.0015 and p<0.04, respectively), but similar
basal cortisol levels in patients and controls
Ryan et al. (2004a) and Walsh et al. (2005) found evidence of
increased basal ACTH and cortisol in ﬁrst-episode, drug-
naive schizophrenia patients versus controls
Shirayama et al. (2002) only found evidence of increased
basal ACTH in patients with moderate negative symp-
toms (p<0.05), in contrast to those with low negative
symptoms where ACTH did not diﬀer between patients
and controls.
Discussion
The aim of this systematic review was to ﬁrstly examine HPA
axis function in people with schizophrenia, and then to assess
if any evidenced dysfunction could be contributing to the
poor physical health and premature mortality seen in patients
with schizophrenia. The two most commonly studied areas of
HPA axis function, i.e. the direct measurement of basal cor-
tisol and the DST, provided highly heterogeneous results,
making interpretation complex and ﬁrm conclusions on the
state of HPA axis function in schizophrenia diﬃcult. Other
areas examined, such as the HPA axis response to psycholog-
ical stressors, provided more consistent ﬁndings, but results
are still open to interpretation. Despite these complexities,
this review has identiﬁed a number of signiﬁcant diﬀerences
between schizophrenia patients and controls, indicating there
may be clinically relevant HPA axis dysfunction in patients
with schizophrenia. These ﬁndings are discussed below along
with possible confounders. Finally, the role of these changes
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Study Subjects
Illness phase and setting and
medication use Measurement details Findings
Brambilla et al.
(1984)
37 SCH
21 CON
Drug free  10 days. All had severe
thought disorder and delusions
Plasma ACTH 09.00 Basal ACTH SCH¼CON although 14
SCH patients had basal ACTH
above the CON range
Nemeroff et al.
(1984)
11 SCH
10 CON
Drug free for  2 weeks, setting and
illness phase not stated.
CSF CRH 09.00 CSF CRH SCH¼CON
Roy et al.
(1986)
9 SCH
27 CON
Recently hospitalized, acutely psy-
chotic. Drug free for  2 weeks
Plasma ACTH and cortisol Basal ACTH and cortisol SCH¼CON
Banki et al.
(1987)
23 SCH
138 neurological CON
Recently hospitalized, severely ill,
drug free for  2 weeks
CSF CRH 09.00–10.00 (4–7
days after admission)
CSF CRH SCH>CON (p<0.001) 6/23
(26%) of SCH subjects had CRH
higher than the highest CON value
van Cauter et al.
(1991)
9 SCH
9 CON
Drug free for 3 weeks. Neuroleptic
free for 9 weeks. Recently hospi-
talized for exacerbation of chronic
illness
24-h plasma corticotropin
(ACTH) and cortisol mea-
sured at 15-min intervals
Circadian rhythm of cortisol secretion
was normal in SCH
ACTH SCH¼CON at all times
over 24-h period
24-h cortisol SCH¼CON
Cortisol SCH>CON from 00.00 to
04.00 hours (p<0.01)
Banki et al.
(1992)
91 SCH 29
neurological CON
Recently hospitalized, actively psy-
chotic, drug free for  2 weeks
CSF CRH 09.00–10.00 (3–6
days after admission)
CSF CRH SCH¼neurological CON
Kathol et al.
(1992)
5 SCH
13 CON
SCH inpatients drug free for  2
weeks
Plasma ACTH and cortisol
(at 16.00)
Basal ACTH trended to SCH<CON
(p¼0.07)
Basal cortisol SCH¼CON
Risch et al.
(1992)
45 SCH
94 CON
Drug free for 1 week. No indication of
illness phase but admitted for
study
CSF CRH and ACTH (obtained
07.00–09.00) 24-h UFC
UFC SCH¼CON
CSF CRH and ACTH SCH¼CON
Lammers et al.
(1995)
24 SCH
24 CON
9 patients drug free for 3 months, the
rest treated with clozapine and
typical neuroleptics
Plasma ACTH and cortisol Basal ACTH tended SCH>CON
(p<0.08)
Basal cortisol SCH>CON
(p<0.01)
Kudoh et al.
(1997)
22 SCH
20 CON
All receiving FGA, chronic but stable Plasma ACTH and cortisol Basal ACTH SCH<CON p<0.05)
Basal cortisol SCH¼CON
Elman et al.
(1998)
13 SCH
11 CON
Out patients all receiving FGA Plasma ACTH and cortisol Basal ACTH and cortisol SCH¼CON
Nishino et al.
(1998)
12 SCH
14 CON
Drug free for  2 weeks
Hospitalized inpatients
CSF CRH obtained 07.00–
08.00
CSF CRF SCH¼CON
Duval et al.
(2000)
41 SCH
27 CON
Hospitalized SCH drug free for  2
weeks
Plasma ACTH and cortisol
(08.00)
Basal ACTH and cortisol SCH¼CON
Hundt et al.
(2001)
7 SCH
10 CON
Inpatients with negative and without
psychotic symptoms. Drug free for
 7 days
Plasma ACTH and cortisol
(every 30min from 09.00–
11.00)
Basal ACTH SCH¼CON
Basal cortisol SCH¼CON
Kaneda et al.
(2002)
53 SCH
23 CON
Chronically medicated inpatients Plasma ACTH and cortisol
(06.00–07.00)
Basal ACTH SCH>CON (p¼0.0015)
Basal cortisol SCH¼CON
Shirayama et al.
(2002)
28 SCH
13 CON
In and outpatients with stable sx and
an absence of positive sx. Patients
split into low (n¼14) and mod-
erate negative sx groups (n¼14).
All patients on neuroleptics
Plasma ACTH and cortisol
(single sample between
08.30–11.30)
Basal ACTH SCH with moderate neg-
ative sx SCH>CON (p<0.05)
Basal ACTH SCH with low negative
Sx SCH¼CON
Basal cortisol SCH with moderate
negative sx>CON (p<0.01)
Basal cortisol SCH with low nega-
tive sx SCH¼CON
Yazici et al.
(2002)
58 SCH
30 CON
Admitted SCH patients. Drug free for
 1 week
Plasma ACTH obtained at
08.00, cortisol at 09.00)
Basal ACTH and cortisol SCH¼CON
Duval et al.
(2003)
20 SCH
23 CON
SCH inpatients. 11 drug naı ¨ve, 9 drug
free for >2 years
Plasma ACTH and cortisol
(07.00–09.00)
Basal ACTH and cortisol SCH¼CON
(continued)
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disease and premature mortality in schizophrenia patients.
Basal HPA axis activity
Basal cortisol is assumed to be a measure of the secretion of
cortisol in the unstressed or resting state and would give an
indication of hyper-, hypo- or normal cortisol secretion under
basal conditions. This systematic review found evidence of
elevated basal cortisol in some but not all schizophrenia
patients compared with controls. However, measurement of
basal cortisol is confounded by several factors, which may
account for the heterogeneous results described. Most impor-
tantly, psychological stress inﬂuences cortisol secretion and,
for this reason, a fair comparison of basal cortisol secretion
between patients and controls would require both groups to
be under similar levels of psychological stress. In practical
terms this is very diﬃcult to achieve for a number of reasons.
Schizophrenia patients are exposed to a broad range of psy-
chological stressors; some true stressors experienced by the
population at large, but others which can be termed ‘pseudos-
tressors’ (Dinan, 2004). These emanate from subjective space
and are only experienced by people with schizophrenia and
other psychotic illness. They are represented by the core
symptoms of schizophrenia such as delusions and hallucina-
tions, and can have profound emotional intensity. They are
likely quite diﬀerent to the stresses experienced by the rest of
the population. Given the behavioural disturbance these
symptoms can produce, it is reasonable to assume they may
inﬂuence endocrinological changes in the HPA axis. It is also
quite possible that the type of psychotic symptoms, and the
perception of these symptoms as stressful or not by the indi-
vidual, will inﬂuence the cortisol level. For example, acute
persecutory delusions are more likely to be perceived as
stressful by an individual than delusions of grandeur, and
therefore may inﬂuence cortisol secretion diﬀerently. The
type of stress and whether it is social-evaluative and uncon-
trollable has been demonstrated to inﬂuence cortisol level in
healthy subjects (Dickerson and Kemeny, 2004) and may also
be applicable to those with schizophrenia (Jones and
Fernyhough, 2007). Many studies of basal cortisol and the
DST included symptomatic patients, many of whom were
acutely psychotic and were therefore likely to be under diﬀer-
ent levels and types of stress than the control populations.
It is therefore diﬃcult to interpret whether any diﬀerences
in cortisol level are due to diﬀerent levels of stress experienced
by patients compared with controls, or to a diﬀerence in basal
function of the HPA axis.
Patients were also frequently hospitalized due to their clin-
ical condition, and this too may be experienced as a stressful
event by a patient, thus also invoking an increased stress
response. Another confounding factor may be the use of anti-
psychotic medications. Antipsychotics can inﬂuence cortisol
levels in several ways. First, by reducing the symptoms of
schizophrenia they may reduce the levels of pseudostress asso-
ciated with psychotic illness and consequently also reduce
cortisol levels. Second, antipsychotics may inﬂuence the secre-
tion of cortisol as a direct result of their pharmacological
actions and mask the HPA axis hyperfunction seen in the
untreated state. It has previously been discussed that the
reduction of cortisol seen during clozapine treatment could
be a non-speciﬁc reduction in stress-induced activation of the
HPA axis or a direct eﬀect of clozapine on cortisol secretion
(Meltzer, 1989). This eﬀect has also been examined in healthy
subjects in order to negate the eﬀect of improving symptom
expression on cortisol secretion. Evidence suggests that ﬁrst-
generation antipsychotics have little eﬀect on cortisol level in
healthy subjects, but that second-generation drugs, notably
olanzapine, quetiapine and clozapine, reduce ACTH and cor-
tisol levels, possibly through their serotonergic, adrenergic
and histominergic activities (Cohrs et al., 2006).
This systematic review found evidence of elevated basal
cortisol in some schizophrenia patients compared with con-
trols, but in terms of whether this actually evidences any dys-
function of the HPA axis or reﬂects the phase of illness and/or
clinical setting, and therefore diﬀerences in perceived stress
levels between patients and controls, needs careful interpreta-
tion in view of the above confounders.
Evidence for elevated cortisol was found most consistently
in ﬁrst-episode, drug-naive schizophrenia patients. Studies in
these patients are free from the confounding eﬀects of medi-
cation. However, in all of these studies, patients were likely
to be experiencing some level of psychological stress either
due to their psychotic symptoms and/or admission to a
Table 7 Continued
Study Subjects
Illness phase and setting and
medication use Measurement details Findings
Ryan et al.
(2004b)
12 SCH
12 CON
Hospitalized first episode drug naive Plasma ACTH, AVP and corti-
sol (at 20-min intervals
13.00–16.00)
Basal cortisol and AVP SCH¼CON
Basal ACTH SCH>CON (p<0.05)
AUC ACTH SCH>CON (p<0.02)
AUC cortisol SCH>CON (p<0.01)
AUC AVP SCH<CON (p<0.02)
Walsh et al.
(2005)
10 SCH
10 CON
Hospitalized, first episode, drug
naive
Plasma ACTH and cortisol
(at 13.00)
Basal ACTH SCH>CON (p<0.001)
Basal cortisol SCH>CON
(p<0.02)
Brunelin et al.
(2008)
15 SCH
15 FDR
14 CON
Remitted outpatients admitted for
study. All receiving SGA
Plasma ACTH and cortisol Basal ACTH varied across groups
(p<0.04): SCH 19.8 (8.7), FDR
12.6 (5.6), CON 16.6 (7.4) ng/mL
Basal cortisol SCH¼FDR¼CON
AVP, arginine vasopressin, FDR, first-degree relatives, antipsychotic, UFC, urinary free cortisol. For other abbreviations, see Tables 1. 2 and 4.
Bradley and Dinan 105psychiatric hospital. For this reason it is not possible to con-
clude that these studies provide evidence of HPA axis dys-
function per se, as the elevated cortisol levels commonly
found could be the result of a normal HPA axis response to
stress. In one of these studies, symptoms were mild to mod-
erate and hospital admission was voluntary (Ryan et al.,
2004b), but it is still not possible to entirely rule out the eﬀects
of the stress associated with the patients’ clinical condition or
setting. In another ﬁrst-episode study reported by the same
group (Ryan et al., 2004a), patients were only mildly ill at
entry but were hospitalized with a mean brief psychiatric
rating scale (BPRS) score of 32.1 (þ/ 1.8). At baseline,
these patients had signiﬁcantly higher cortisol than control
subjects (p<0.003). Following 6 months of treatment with
either olanzapine or risperidone, mean BPRS scores had
fallen to 21.6 (þ/ 0.8) and patients were presumably dis-
charged from hospital. This was accompanied by a signiﬁcant
reduction in cortisol from the pre-treatment mean (p<0.05).
Decreased cortisol levels in these patients could be due to
successful treatment of schizophrenia symptoms with a resul-
tant reduction of stress, or to the direct eﬀect of antipsy-
chotics on cortisol secretion.
Although the study reported by Strous et al. (2004) found
no diﬀerence in basal cortisol between ﬁrst-episode schizo-
phrenia patients and controls, it did demonstrate signiﬁcant
associations of cortisol with negative (r¼0.35, p¼0.036), gen-
eral (r¼0.35, p¼0.034) and total positive and negative syn-
drome scale (PANSS) scores (r¼0.33, p¼0.045). In this
study, levels of the adrenal steroid dehydroepiandrosterone
(DHEA) and its sulphated form DHEA-S were signiﬁcantly
elevated in schizophrenia patients. These steroids have anti-
glucocorticoid activity and have been shown to reduce cortisol
levels in healthy individuals (Wolf et al., 1997). They could,
therefore, explain the non-elevation of cortisol in this group.
Venkatasubramanian et al. (2007, 2010) and Spelman et al.
(2007) found elevated cortisol levels in drug-naive patients
and, in contrast to Strous et al. (2004), found no direct asso-
ciation of cortisol with psychopathology scores. However, in
the Venkatasubramanian et al. (2010) study, treatment with
primarily olanzapine and risperidone resulted in both symp-
tom and cortisol reduction and an increase in insulin-like
growth factor-1 (IGF-1). Furthermore, the greater the
increase in IGF-1, the greater the reduction in positive symp-
toms (r¼0.39, p¼0.02). That there was also a signiﬁcant pos-
itive correlation between the magnitude of increase in IGF-1
level and the magnitude of reduction in cortisol level (r¼0.52,
p¼0.002) indicates cortisol may be indirectly associated with
positive symptoms possibly via its eﬀects on IGF-1.
The DST is a test of delayed feedback mechanisms in the
HPA axis which may then lead to hypersecretion of cortisol.
In the only study using the DST in ﬁrst-episode schizophrenia
patients, Ceskova et al. (2006) found an association of anxiety
with pre-treatment cortisol levels in mostly drug-naive
patients. There was a DST non-suppression rate of 17.9%
at medication-free baseline and, following acute treatment,
a signiﬁcant association of post-DEX cortisol with negative
symptoms was found. After acute treatment and clinical
improvement, the number of non-suppressors to the DST
had fallen to 5.3% and was 16.1% after 1 year. This increase
in DST non-suppressors after 1 year was partially explained
by clinical deterioration and non-compliance in some
patients. Collectively, these studies demonstrate that cortisol
level may be associated with the symptoms of schizophrenia
and may decrease with improving clinical picture.
A possible weakness of this systematic review is that some
studies that did not meet the inclusion criteria may still pro-
vide useful information of HPA axis function in schizophre-
nia. Two studies, not included in this review due to the absence
of a control group, add strength to the view that cortisol level
may be related to symptoms. Sachar et al. (1970) measured
glucocorticoid levels across illness phases in ﬁrst-episode psy-
chosis diagnosable as acute schizophrenic reaction. Four male
patients were managed as inpatients by intensive nursing with-
out the use of antipsychotic medication. Twenty-four hour
urinary 17-hyydroxycorticosteroid (17-OHCS) and 08:00
plasma 17-OHCS were measured several times a week. The
period of acute psychotic turmoil was associated with a
marked 250% increase from basal levels of corticosteroid in
each patient. Corticosteroids fell to normal levels in one
patient following development of an organized psychotic
system and then rose again as the patient moved into a depres-
sive phase of illness. In the other three patients, corticosteroid
levels reduced through a recovery phase and returned to basal
levels ontotal recoveryand discharge. These observations pro-
vide evidence for a relationship between symptoms, phase of
illness and cortisol level in ﬁrst-episode patients without the
complication of medication use. However, for ethical reasons,
this study is unlikely to be replicated today. Franzen (1971)
reported the association of cortisol with symptoms in 18
female, medicated, chronic schizophrenia patients by measur-
ing 24-h serum cortisol and correlating with symptoms mea-
sured by the RP scale, which quantiﬁes mental status in
psychotic patients (Rockland and Pollin, 1965). A relationship
between mental status and diurnal rhythm of serum cortisol
was found such that elevated morning cortisol and a steeper
declination of the cortisol diurnal curve correlated with anxi-
ety, thought disorder and delusions and paranoid traits.
Associations of symptoms and cortisol levels have also
been explored in chronic rather than acutely ill patients.
Christie et al. (1986) found that morning plasma cortisol
levels correlated with BPRS score (p<0.05). Patients diag-
nosed with schizophrenia using RDC had signiﬁcantly ele-
vated afternoon cortisol compared with controls, but in
schizophrenia patients classiﬁed according to the criteria of
Feighner (Feighner et al., 1972), which yielded a group of less
acutely ill patients, there were no diﬀerences in cortisol levels,
suggesting increased cortisol may be linked to symptoms.
Studies have also found an association of cortisol with nega-
tive symptoms. Altamura et al. (1989) reported that patients
with prominent negative symptoms and low levels of positive
symptoms had similar basal cortisol at 08:00 but signiﬁcantly
higher basal cortisol at 16:00 (p<0.01) than patients with
prominent positive symptoms and low levels of negative
symptoms. Shirayama et al. (2002) examined schizophrenia
patients with an absence of positive symptoms who were clin-
ically stable for 2 months before the study. Patients were
grouped into moderate and low negative symptoms, based
on the scale for assessment of negative symptoms (SANS).
Only those with moderate negative symptoms had signiﬁ-
cantly elevated cortisol compared with controls.
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patients had signiﬁcantly higher cortisol levels than controls
both pre- and post-treatment; cortisol signiﬁcantly reduced
from baseline during treatment with both risperidone and
haloperidol, although to a signiﬁcantly greater degree with
risperidone (p¼0.014) Cortisol was signiﬁcantly correlated
with negative symptoms at both baseline (r¼0.28, p¼0.02)
and post-treatment (r¼0.34, p¼0.005) and with PANSS
total score post-treatment (r¼0.30, p¼0.01). The study
reported by Breier et al. (1988a) found no association of
basal ACTH or other neuroendocrine measures with global
psychosis.
As described earlier, studies of the DST in schizophrenia
patients have also looked for correlations of symptoms with
non-suppression of cortisol which would indicate a faulty
feedback mechanism in the HPA axis. The results indicated
there is no consistent association of post-DEX cortisol or
non-suppression with negative, depressive or positive symp-
toms. This variation in the ﬁndings could be due to a number
of factors that are thought to possibly aﬀect DST results,
including severity of illness, age, gender, stress level, medica-
tion use and plasma DEX levels. This review did not ﬁnd any
signiﬁcant eﬀects of medication on DST outcome, with 29.4%
of patients who were drug free for >2 weeks non-suppressors
compared with 25.5% of medicated patients. The DST studies
did, however, provide some evidence that non-suppression
rates may vary over time in individual patients and also
change with acute response to treatment. This is evidenced
by studies where the DST was performed on hospital admis-
sion while patients were acutely psychotic and again after
acute treatment with antipsychotic medications. All these
studies showed reductions in the non-suppression rate at the
follow-up DST. However, it is possible that this reduction in
non-suppression rates was caused by reduction in symptoms
and the likely accompanying reduction in stress during treat-
ment, or possibly as a direct result of antipsychotics.
However, the antipsychotics used were all ﬁrst-generation
drugs which, as previously stated, do not appear to have a
direct eﬀect on cortisol secretion.
There are three previously published reviews of the DST in
schizophrenia. In a meta-analysis, Sharma et al. (1988)
reported a non-suppression rate of 19% compared with
51% in major depression and 7% in controls. This meta-
analysis applied diﬀerent inclusion criteria to the present
analysis: all studies had to include both depressed and schizo-
phrenia patients, but the dose of DEX used in the DST could
be 0.5, 1.0 or 2.0mg. The meta-analysis reported by Yeragani
(1990) found a non-suppression rate of 26.4% in schizophre-
nia versus 5.0% in controls. Tandon et al. (1991), in a sum-
mary meta-analysis, found a DST non-suppression rate of
36% in the drug-free state and 20% in the medicated state.
Several other variables may have also have aﬀected the results
of these and the present analyses. For example, the lack of a
control group to establish the cortisol level cut-oﬀ for the
assay used could account for some of the variability in results
in many studies. Furthermore, blood levels of DEX were
rarely measured to ensure compliance or to investigate the
eﬀects of diﬀerent blood levels of DEX on outcome.
In contrast to the large numbers of patients with basal
cortisol measures, few studies have measured basal levels of
other components of the HPA axis. CRH levels were only
measured in ﬁve studies, all in CSF. In only one of these
(Banki et al., 1987) was there any evidence of increased
basal levels of CRH, although this was largely due to extre-
mely high levels in three individuals. Furthermore, it is
unclear if CSF CRH accurately represents the concentration
of CRH in the hypophyseal portal system.
The studies measuring basal ACTH produced mixed
results. Statistically signiﬁcantly elevated ACTH was reported
in only four studies (Brunelin et al., 2008; Kaneda et al., 2002;
Ryan et al., 2004a; Walsh et al., 2005). Although the study
reported by Brambilla et al. (1984) found no signiﬁcant dif-
ference in basal ACTH level, 14/37 (38%) schizophrenia
patients had a basal ACTH level above the range of the con-
trol group, providing more evidence that at least some schizo-
phrenia patients have elevated ACTH levels. In the Brunelin
et al. (2008) and Kaneda et al. (2002) studies increased ACTH
was not matched by increased basal cortisol level, but in Ryan
et al. (2004a) and Walsh et al. (2005), both of which were
studies in ﬁrst-episode, drug-naive patients, signiﬁcantly ele-
vated ACTH and cortisol levels were found. Kudoh et al.
(1997) reported signiﬁcantly lower basal ACTH (p<0.05)
but similar basal cortisol in schizophrenia and controls.
These data collectively suggest that, in some patients, the ele-
vated cortisol levels commonly measured in schizophrenia
may also be stimulated by a mechanism other than increased
CRH and ACTH. Ryan et al. (2004b) have proposed a mech-
anism for elevated cortisol involving arginine vasopressin
(AVP). In this study, although ACTH was elevated in schizo-
phrenia patients, it was not correlated with cortisol, suggest-
ing it had another cause. The AVP AUC from 13:00 to
16:00 was actually lower in schizophrenia patients than in
controls (p<0.02), but there was a signiﬁcant positive corre-
lation between plasma AVP and cortisol (r¼0.66, df¼10,
p<0.02) and between the AUC AVP and AUC cortisol
(r¼0.68, df¼10, p<0.05). The authors suggest this signiﬁ-
cant positive association of AVP with cortisol may be
explained by the fact that AVP can directly stimulate cortisol
release from the adrenal cortex (Guillon et al., 1995) and
therefore, in these patients, may have been responsible for
hypersecretion of cortisol. Other studies have also reported
a lack of association between ACTH and cortisol level in
schizophrenia. Breier et al. reported no correlation between
cortisol and ACTH, either during metabolic stress induced by
the eﬀects of 2-deoxy-D-glucose (which reduces glucose level)
(Breier et al., 1988b), or psychological stress induced by a
lumbar puncture procedure (Breier et al., 1988a).
Evidence is accumulating of other factors that may signif-
icantly aﬀect the integrity and function of the HPA axis and
therefore signiﬁcantly inﬂuence outcomes in these studies.
Some of these factors are particularly applicable to people
with schizophrenia. For example, HPA axis function may
be inﬂuenced by exposure to maternal stressors such as
foetal malnutrition (Phillips and Jones, 2006) and psycholog-
ical stress experienced by the mother during pregnancy
(Glover et al., 2009) in a process termed foetal programming.
These stressors may be expressed as a low birth weight or
minor physical anomalies in the infant. Studies have demon-
strated that low birth weight is associated with enhanced
HPA axis and autonomic response to experimentally induced
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is an illness associated with low birth weight (Cannon et al.,
2002) and an increased incidence of minor physical anomalies
(Compton and Walker, 2009), which may indicate increased
exposure to a variety of maternal stressors. As these factors
are more common in people with schizophrenia, they may
have a greater inﬂuence on HPA function in schizophrenia
patients and may contribute to the diﬀerences in HPA func-
tion seen between patients with schizophrenia and controls, as
well as accounting for some of the variation in HPA function
within the schizophrenia population. This potential is illus-
trated by Mittal et al. (2007) who demonstrated that schizo-
typal adolescents express signiﬁcantly more minor physical
anomalies than normal controls, and that these predict corti-
sol elevation.
Another factor is childhood trauma, which is associated
with sensitization of the stress response, glucocorticoid resis-
tance, increased CRH activity, immune activation and
reduced hippocampal volume (Heim et al., 2008). Several
studies have directly illustrated the eﬀect of childhood
trauma on HPA axis function. In a study of female youths
maltreated during childhood (e.g. physical, sexual and emo-
tional abuse), a blunted cortisol response to the Trier Social
Stress Test was found compared with controls (MacMillan
et al., 2009). Elzinga et al. (2008) also measured the cortisol
response to the Trier Social Stress Test in people exposed to
various levels of adverse life events such as emotional, phys-
ical or sexual abuse but with similar baseline cortisol levels.
A signiﬁcant blunted cortisol response was found in individ-
uals with a history of adverse life events compared with indi-
viduals with no such events. This ﬁnding was primarily driven
by the result in men.
Childhood trauma has been shown to be predictive and
probably causal in the development of psychosis (Read et al.,
2005; Shevlin et al., 2008), and it is therefore reasonable to
assume that diﬀerences in the frequency and severity of child-
hood traumas in the schizophrenia populations studied could
also explain some of the variance in the results. The potential
for such an eﬀect was seen in a recent study. Mondelli et al.
(2010) found a signiﬁcant negative correlation between the
number of stressful life events and cortisol level (r¼ 0.36,
p<0.014) in ﬁrst-episode, psychotic patients including schizo-
phrenia and schizophreniform disorder. The control group, as
expected, had a positive correlation between the number of
stressful life events and cortisol level (r¼0.42, p<0.013). The
authors hypothesized that the unexpected negative correla-
tion in psychotic patients may be explained by the excessive
load of stressful life events experienced in this patient group.
Stressful life events were experienced on average at around
three times the rate in the psychotic cohort compared with the
controls, and 85.7% of the psychotic patients had experienced
a childhood trauma compared with 38.7% of controls.
Furthermore, patients with post traumatic stress disorder
(PTSD) caused by the extreme stress of physical or sexual
abuse (that normally begins in childhood) show cortisol hypo-
secretion (Meewisse et al., 2007), suggesting that some forms
of extreme stress may decrease HPA axis activation. In the
Mondelli et al. study (2010), patients in the top 20th percen-
tile for the number of stressful life events had similar cortisol
levels as healthy controls, and it could therefore be that
variations in exposure to extreme childhood trauma may
account for some of the variation seen in the outcomes of
the basal cortisol studies included in this review.
This systematic review found evidence in four studies that
basal cortisol was signiﬁcantly lower in schizophrenia patients
than controls. CSF cortisol was measured in the study
reported by Gattaz et al. (1985). Drug-free schizophrenia
patients were found to have signiﬁcantly lower cortisol than
the control subjects who had non-speciﬁc neurological symp-
toms such as headache or dizziness. Wik (1995) studied newly
admitted schizophrenia patients whose baseline cortisol was
similar to controls. After 5–6 weeks of treatment with sulpir-
ide or chlorpromazine, mean cortisol level was signiﬁcantly
lower than in the control group (p<0.001). The authors con-
cluded that the reduction of cortisol was caused by the anti-
psychotics, but patients also presumably had a reduction in
symptoms and it is therefore not possible to conclude this
with any conﬁdence. It is also quite possible that following
antipsychotic treatment, patients reverted to their symptom
and stress-free basal cortisol levels, which were lower than
those of the control group.
In a study by Monteleone et al. (1994), lower basal cortisol
was consistently reported in a cohort of schizophrenia
patients compared with controls in each of November,
February and May. These patients had received chronic treat-
ment with ﬁrst-generation antipsychotics but were still symp-
tomatic (mean SAPS score across the three timepoints
approximately 40, and SANS score approximately 37). The
other study reporting signiﬁcantly lower basal cortisol in
schizophrenia patients (Taherianfard and Shariaty, 2004)
also found consistent evidence for reduced cortisol level.
Cortisol was measured at three time points: in the drug-free
state on admission to hospital, during treatment with antipsy-
chotics, and on recovery. Cortisol level was signiﬁcantly lower
than in the control group at all three time points and did not
change signiﬁcantly from baseline at any time point. No
information was given about the level of symptoms in these
patients, but the ﬁndings suggest that some schizophrenia
patients may experience hyposecretion of cortisol even when
symptomatic and, as suggested by Mondelli et al. (2010), this
could possibly relate to high exposure to signiﬁcant stressors
earlier in life. Of interest, a study reported by Mason et al.
(1986) found that the low levels of cortisol in patients with
paranoid schizophrenia were similar to those in patients with
PTSD. Furthermore, these were signiﬁcantly lower than in
patients with bipolar disorder, depression or undiﬀerentiated
schizophrenia, although there was no non-psychiatric control
group. The authors suggest that this low cortisol level may be
maintained by a paranoid system of adaption, as also seen in
the small study by Sachar (1970). These hypotheses may also
explain the ﬁnding from many studies of no signiﬁcant diﬀer-
ence in cortisol level between patients and controls. This ﬁnd-
ing was reported even where patients were acutely ill and
admitted to hospital where an increased level of cortisol
might be expected (for example, Duval et al., 2003; Strous
et al., 2004; Wik, 1995). It is conceivable, given the evidence
from Mondelli et al. (2010), that some patients with schizo-
phrenia who have experienced signiﬁcant levels of life stress
or perhaps childhood trauma may actually hyposecrete cor-
tisol. In many studies where the schizophrenia cohort would
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mean cortisol level and therefore may explain why many stud-
ies found no signiﬁcant diﬀerences in basal cortisol level
between schizophrenia patients and controls. One small
study gives credence to this hypothesis but needs replication
in a larger cohort. Braehler et al. (2005) reported that schizo-
phrenia patients who had experienced childhood trauma
tended to have lower 24-h salivary free cortisol than patients
with low levels of childhood trauma (p¼0.011). Cortisol was
signiﬁcantly lower in the childhood trauma group in the ﬁrst
hour after wakening, and was signiﬁcantly negatively associ-
ated with emotional and sexual abuse. This study could not
be included in the systematic review as it did not include any
non-psychiatric controls.
CRH test and DEX/CRH test
Few studies have measured the response of the HPA axis to
CRH in schizophrenia patients. The CRH test has only been
reported once in drug-free and medicated patients with
schizophrenia and results did not diﬀer from controls, sug-
gesting an intact HPA axis function (Roy et al., 1986).
However, this study was small (n¼9) and patients showed
various levels of psychosis. There was a trend towards a neg-
ative ACTH response with psychosis rating (r¼ 0.42,
p<0.1), suggesting ACTH response may be blunted in a
more uniformly psychotic cohort. More studies using the
CRH test are needed before any ﬁrm conclusions can be
drawn.
The DEX/CRH test is thought to be more sensitive to
subtle HPA system changes than the DST, but only one
study reporting results of the DEX/CRH test in schizophrenia
patients could be included in this review. Lammers et al.
(1995) demonstrated that following pre-treatment with
DEX, schizophrenia patients released more cortisol in
response to CRH than controls. This was particularly so in
drug-free patients who had higher BPRS scores than in med-
icated, less severely ill patients. Like the analysis of basal
cortisol and DST, this suggests that illness phase may inﬂu-
ence cortisol secretion. However, it is not possible to deter-
mine if reduction in cortisol secretion was related to lower
levels of symptoms or the use of medication, as many of the
medicated patients were taking clozapine, a drug known to
have a direct eﬀect on cortisol secretion. This study suggests
that the mechanism of cortisol hypersecretion in these
patients may be due, in part, to impaired negative feedback
mechanisms, since this occurred following DEX. Of note, the
cortisol response was increased in patients despite no signif-
icant diﬀerence in ACTH AUC between patients and controls
over the course of the test, suggesting an explanation other
than increased ACTH for the increase in cortisol, which may
agree with the ﬁndings of Ryan et al. (2004b) and Breier et al.
(1988a, 1988b).
Psychological stress and HPA axis response
in schizophrenia
Since psychological stress may be important in the develop-
ment and course of schizophrenia, studies that measure the
reaction to psychological stress could be important in under-
standing how environmental factors contribute to pathogen-
esis of the disease. Studies measuring HPA axis response to
psychological stress in schizophrenia patients produced con-
sistent results, demonstrating a blunted ACTH and cortisol
response to stress. The results were the same in drug-free,
medicated, acutely psychotic and more chronic patients, sug-
gesting these factors did not aﬀect the outcomes of the stud-
ies. Where heart rate and mean arterial pressure were
measured, increases in schizophrenia patients were similar
to those in controls, indicating that patients found the tests
stressful and that the physical response to stress was intact.
A variety of explanations have been suggested for these
results. Breier et al. (1988a) suggested that the blunted
ACTH and cortisol stress response may partly be due to the
signiﬁcant negative correlation between the levels of psychosis
and stress-induced increases in ACTH, i.e. the greater the
psychosis, the lesser the increase in cortisol. They suggest it
is possible that cognitive and/or neurobiological processes
associated with severe psychosis have a disruptive eﬀect on
mechanisms involved in mounting a neuroendocrine stress
response. In the study reported by Jansen et al. (2000), the
cortisol response in schizophrenia patients to a physical
stress, exercise, was not diﬀerent from controls, and they sug-
gest the blunted cortisol response to a psychological stress
could be due to the diﬀerent mechanisms of HPA axis acti-
vation to diﬀerent types of stress. They cite evidence that
physical stressors invoke a response via CRH and, as
described in this review, CRH function appears relatively
normal in schizophrenia patients, hence the normal stress
response to exercise. Psychological stress stimulates the
HPA axis via AVP (Romero and Sapolsky, 1996) which
may be diminished in schizophrenia patients (Marx and
Leiberman, 1998), resulting in a blunted cortisol response to
psychological stress. The hypothesis proposed by Ryan et al.
(2004b), that AVP may be responsible for hypersecretion of
cortisol in ﬁrst-episode patients via its ability to stimulate
cortisol release directly from the adrenal gland, is seemingly
at odds with this. They too found a reduction of AVP com-
pared with controls, although the eﬀects of AVP would have
been augmented by the increased level of ACTH seen in their
patients, which together could have accounted for the
increased cortisol level.
Jansen et al. (2000) also suggest that the impaired stress
response may be due to diﬀerences in coping strategies used
by people with schizophrenia compared with controls. They
found that schizophrenia patients used more passive and
avoidance strategies compared with controls, which may
invoke a diﬀerent biological stress response. In the study
reported by Brenner et al. (2009), although there was a
trend towards lower cortisol secretion during psychological
stress, it was suggested that cortisol secretion may just be
delayed. This is based on the observation that cortisol levels
were signiﬁcantly lower at one time point during the study but
were subsequently similar, suggesting the cortisol response
was initially delayed but ultimately caught up. This group
proposes that this could be due to impairment in executive
functions where patients were less able to think ahead before
the task, and therefore the stress associated HPA axis
response was delayed. This view may be supported by
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cognitive appraisal of acute stressors explained up to one-
third of the variance observed in cortisol response to stress.
This cognitive appraisal could, of course, be impaired in
schizophrenia patients. Brenner et al. (2009) also suggest
that physiological diﬀerences in the HPA axis such as a
hypoactivity could explain the delay in cortisol response.
Hypofunction of the HPA axis during stress tests was also
demonstrated by MacMillan et al. (2009) and Elzinga et al.
(2008), in studies that found a blunted cortisol stress
response to psychological stress in patients previously
exposed to signiﬁcant life stress. It is possible that in the
schizophrenia cohorts studied, the rate of exposure to signif-
icant life stressors may have been greater in patients than in
controls.
HPA axis function in schizophrenia: Implications for
physical health and mortality
It is beyond the scope of this review to give detailed explana-
tions of the role of stress and the HPA axis in the develop-
ment of physical illness and premature mortality. Many
excellent articles are already available, and the reader is
referred to Benarroch (2005), Kyrou and Tsigos (2009), and
Rosmond (2005) for the role of the HPA axis in metabolic
and cardiovascular disease, Juster et al. (2010) for chronic
stress, allostatic load and their impact on health, and Heim
et al. (2000) and Raison and Miller (2003) for reviews of
hypofunction of the HPA axis and physical health.
Figure 1 shows how the stress cascade can lead to physical
ill health. Put simply, the HPA axis is a crucial system in
maintaining homeostasis and adapting to the environment;
it achieves this largely through the secretion of cortisol with
subsequent eﬀects on target organs. Prolonged exposure to
high levels of cortisol can increase the risk of coronary
heart disease by inducing central obesity, insulin resistance
and lipid abnormalities (Rosmond, 2005).
A recent, large cross-sectional cohort study in patients
with type 2 diabetes also found that elevated plasma cortisol
levels were signiﬁcantly associated with raised fasting glucose
and total cholesterol levels after adjusting for possible con-
founders. Raised cortisol levels also increased the prevalence
of ischaemic heart disease independently of conventional risk
factors (Reynolds et al., 2010). Cortisol also plays an impor-
tant anti-inﬂammatory role by inhibiting the immune activa-
tion caused by acute stress. However, prolonged exposure to
cortisol may render the immune system insensitive to its anti-
inﬂammatory eﬀects via glucocorticoid receptor resistance,
allowing the development of a chronic inﬂammatory state
Figure 1. Reprinted by permission from Macmillan Publishers Ltd. Chrousos GP. Nat Rev Endocrinol 5: 374–381. Copyright 2009.
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as IL-6 (Miller et al., 2009). A pro-inﬂammatory state is evi-
denced in schizophrenia patients by the increased pro-inﬂam-
matory cytokines found in patients with schizophrenia
including IL-6 (Potvin et al., 2008). An increase in IL-6 is
associated with an increased risk of atherosclerosis and type
2 diabetes (Pickup, 2004), and so could plausibly have a role
in the increased incidence of these diseases in schizophrenia.
Similar eﬀects on immune function may also be seen with
an underactive HPA axis, when too little cortisol at times of
stress may allow the acute immune response to continue
unopposed (McEwen, 1998), also resulting in increased
inﬂammation. These two scenarios are both plausible in
schizophrenia patients given the evidence found in this sys-
tematic review. Both prolonged, elevated cortisol and a
blunted cortisol response to psychological stress have been
demonstrated, even in the presence of an increased physical
response to psychological stress. There may also be a subset
of patients who have experienced signiﬁcant childhood trau-
mas with a general hypofunctioning of the HPA axis.
Depending on the pattern of symptoms and treatment, expo-
sure to the stressful eﬀects of psychosis may last many weeks
or even months. In a chronic illness such as schizophrenia,
which is characterized by repeated symptom exacerbation,
over (or sometimes under) exposure to cortisol may continue
for many years. It is thus reasonable to conclude that over
many years the pattern of HPA function in schizophrenia
patients probably contributes to the increased levels of central
obesity, insulin resistance, lipid disturbance and premature
mortality from cardiovascular disease found in this popula-
tion. In schizophrenia there is evidence of increased central
obesity (Ryan et al., 2004a; Thakore et al., 2002) and insulin
resistance (Spelman et al. 2007; Venkatasubramanian et al.,
2007) from the ﬁrst episode in drug-naive patients. These fea-
tures are also commonly found in patients with chronic
schizophrenia (McEvoy et al., 2005), although other factors
such as lifestyle and treatments are also likely to contribute. It
could also be hypothesized that patients with the highest and
most prolonged overexposure to high cortisol levels may
experience the more severe eﬀects of cortisol overexposure.
Therefore it is possible, given the relationship of cortisol
levels with symptoms, course of illness and treatments, that
patients with diﬀerent types of schizophrenia experiencing
diﬀerent symptom patterns and treatments may experience
a diﬀerent pattern of ill-health related to HPA axis function.
There would also likely be a strong inﬂuence from patients
prior exposure to severe stressors, both pre and postnatal,
given the previously described evidence that in utero stress,
birth weight and childhood trauma signiﬁcantly inﬂuence
HPA axis function into adult life.
Another important role of cortisol in mortality may be the
association between cortisol and suicide risk. Suicide is the
leading cause of premature mortality in younger schizophre-
nia patients (Mortensen and Juel, 1993), and therefore this
may be of particular relevance in ﬁrst-episode schizophrenia
and the early years of schizophrenic illness. Several studies in
depressed patients have found an association of DST non-
suppression (Jokinen and Nordstrom, 2009a; Jokinen et al.,
2007; Mann et al., 2006) and suppression with suicide or sui-
cide attempt (Black et al., 2002). Hypoactivity of the HPA
axis (Lindqvist et al., 2008; Pfennig et al., 2005) has also been
associated with suicide attempt. In schizophrenia, Jones et al.
(1994) and Plocka-Lewandowska et al. (2001) found an asso-
ciation of non-suppression in the DST with suicide attempt,
while Lewis et al. (1996) did not. De Luca et al. (2010)
recently reported an association of HPA axis genes with sui-
cide attempt in schizophrenia. These data suggest that HPA
axis genes inﬂuence the stress reactivity of an individual and
therefore the likelihood of that individual to develop a mental
disorder and to attempt suicide. Finally, cortisol itself has
also been demonstrated to be a predictor of mortality in
patients with depression, although there is no current evi-
dence that this is the case in patients with schizophrenia.
Preliminary evidence in two studies of people with depressive
illness suggests that HPA axis dysfunction may be a risk
factor for cardiovascular mortality. Coryell et al. (2008)
found that higher maximum post-DEX cortisol levels pre-
dicted deaths due to cardiovascular causes, and Jokinen and
Nordstrom (2009b) found that higher baseline serum cortisol
and DST non-suppression predicted cardiovascular disease
death, particularly in male patients. One previous study
found no such relationship (Coryell et al., 2006).
Strengths and weaknesses of this review
A major strength of this review is its systematic nature: it
includes all of the published literature to date found by our
search strategy. Although previous reviews have been pub-
lished, none employed a systematic search strategy of HPA
function in schizophrenia. We also included a number of
study types in order to fully understand and accurately
describe HPA function in schizophrenia, including basal mea-
sures, studies using various HPA axis probes and studies
examining HPA axis response to psychological stress. We
only included studies where schizophrenia was diagnosed
using recognized structured interviews in order to exclude
other psychoses which may have a diﬀerent pattern of HPA
function. We did, however, include other diagnoses where
they contributed less than 10% of the overall sample. For
studies using the DST, we only included those that utilized
a standard DST methodology. For studies of psychological
stress tests, we only included studies that used reliable meth-
ods of invoking a stress response.
A weakness of this review is that it is not a meta-analysis.
In theory this would be a useful way to assess whether cortisol
levels are diﬀerent between schizophrenia patients and con-
trols. However, the number of potential confounders makes
this a very diﬃcult, and possibly misleading, task. The time of
cortisol measure was not standardized between studies,
making direct comparisons between studies invalid.
Standard mean diﬀerences between schizophrenia patients
and controls could have been examined, but these may
diﬀer by time of day as cortisol secretion is not uniform
throughout the day and circadian rhythm may be disrupted
in schizophrenia. Also, the number of other confounders both
recognized, such as medication use and phase of illness, and
others unknown, would have made this a very diﬃcult task
producing a possibly misleading outcome. We did not exam-
ine the eﬀects of age, gender or genetics on HPA axis func-
tion, and it is likely these may explain some of the variation in
Bradley and Dinan 111results. It is also possible that some studies excluded from this
systematic review would add useful information to the discus-
sion of HPA axis function in schizophrenia.
Conclusions
Despite the heterogeneity of outcomes from the studies
reviewed, there is evidence that people with schizophrenia
experience periods of heightened cortisol secretion. This con-
sistently occurs at the ﬁrst episode but also occurs in some
chronic patients with more stable clinical features. The var-
iation in results may be explained by varying symptoms of
illness as well as by medication use and exposure to other
environmental factors known to inﬂuence HPA axis func-
tion. Some patients with schizophrenia may also experience
low cortisol levels under certain conditions. This is particu-
larly evidenced by a blunted cortisol response to a psycho-
logical stress test but may also be the case in acutely ill
patients, as many studies found no evidence of elevated cor-
tisol in psychotic patients admitted to hospital where a stress
response would reasonably be expected. In view of the
strong evidence in the general population, this pattern of
HPA axis function is also likely to signiﬁcantly contribute
to the poor physical health (particularly metabolic and car-
diovascular) and premature mortality seen in patients with
schizophrenia.
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